Aptamers

2024 Activity indicators

1 European competitive project: ABSarbo (HE)
6 competitive public projects: ISCIII, MICINN
2 private projects led
2 competitive HR contracts
11 publications
IF: 44.10
Q1 publications: 7 (64%)
D1 publications: 1 (9%)
Evaluators of projects in national institutions: 2 PI
Members of editorial committees: 1 PI
A molecule in clinical trial for the treatment of stroke in 151 patients
9 active patent families with priority patent:
- P201430955 "TLR4-specific Aptamers and their potential use for the treatment of stroke". National phase entry in 15 countries
- P201930524 "FPR2 receptor agonist aptamers" with PCT/ES2020/070378 and national phase entry in the US and Europe
- EP 18 382 888. 8 "Aptamers specific against human MNK1 protein and their use in MNK1 detection method and as MNK1 inhibitor" with PCT/ EP2019/083547 and national phase entry in Europe and USA
- EP17382610 "MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells" with PCT/EP2018/06815 extended in USA and Europe EP22382610 "MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells" with PCT/EP2018/06815 extended in USA and Europe EP22382610. USA and Europe
- EP22382616.5 "DNA aptamer conjugates recognizing and degrading coronavirus proteins"
- EP22382617.3 "DNA aptamer conjugates recognizing and degrading coronavirus proteins"
- EP24382574.2 "OR2AT4 receptor agonist aptamers and uses thereof"
- EP24382947.0 "Aptamer, or pharmaceutical composition thereof, for use in the treatment of pancreatic cancer"
- EP24382233.5 "Nucleic acid aptamer for treatment of liver cancer" EP24382233.5 "Nucleic acid aptamer for treatment of liver cancer"
3 visitors and 6 months stay:
- Instituto Colombiano de Medicina Tropical (Colombia)
- Universidad Peruana de Ciencias Aplicadas (Peru)
- Centro Nacional de Microbiología (Spain)

Milestones

Launch of two new AES2023 (ISCIII) research projects: R&D&I in Health project (PI23/00539) and Fortalece project (FORT23/00046), led by Dr. Víctor M. González.
Award of a project in the Mutua Madrileña Foundation 2024 call to Dr. Ignacio Iturrieta, contracted Rio Hortega in our research group.
Publication of 11 articles in international journals and multiple presentations at national and international conferences.
Signing of 4 research contracts by the UCA Aptamers of the IRYCIS, constituted from the research group and which provides aptamer selection services to third parties, with a research group and three biotechnology companies.
Appointment of Dr. Víctor M. González as Deputy Scientific Director of the IRYCIS.